Drugs / BCG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06350838 | Nov 2022 → Feb 2023 | non-invasive bladder urothelial carcinoma | Chengdu CoenBiotech Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06350838 ↗ |
| Route | Other | “bladder perfusion through catheter” NCT06350838 ↗ |